<DOC>
	<DOC>NCT02333383</DOC>
	<brief_summary>This is a prospective mono-country, multi-center study in Ankylosing Spondylitis (AS) subjects treated with Adalimumab. At least 200 subjects will be enrolled at approximately 10 sites. The baseline assessment should be performed prior to the first dose of Adalimumab. Study visit will be conducted at 12, 28, 36 and 52 week after baseline. All subjects will have one follow-up approximately 70 days after last dose of Adalimumab.</brief_summary>
	<brief_title>Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject must be an adult ≥19 years. Subject has been diagnosed with ankylosing spondylitis (AS) according to the 1984 modified New York criteria for at least 3 months. Subject has active disease defined by a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score ≥4, despite treatment with at least 2 Nonsteroidal antiinflammatory drugs (NSAIDs) or with DMARDs for more than 3 months based on Korea AS reimbursement guideline. Subject is eligible for adalimumab in daily rheumatologic practice. Subject must provide written authorization form to use personal and/or health data prior to the entry into the study. Female subjects who are pregnant or breast feeding. Subject applies contraindication to any antiTNF agent. Subject is participating in other clinical trials.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score</keyword>
	<keyword>EAMs</keyword>
	<keyword>Adalimumab</keyword>
</DOC>